{
  "meta": {
    "title": "57_Myeloproliferative_Diseases_Aplastic_Anemia",
    "url": "https://brainandscalpel.vercel.app/57-myeloproliferative-diseases-aplastic-anemia-c52afa88.html",
    "scrapedAt": "2025-11-30T06:57:29.230Z"
  },
  "questions": [
    {
      "id": 98038,
      "choices": [
        {
          "id": 256395,
          "text": "MDS"
        },
        {
          "id": 256396,
          "text": "PNH"
        },
        {
          "id": 256397,
          "text": "Aleukemia leukemia"
        },
        {
          "id": 256398,
          "text": "All the above"
        }
      ],
      "text": "Pancytopenia with cellular marrow can occur with ?",
      "unique_key": "Q2691409",
      "question_audio": null,
      "question_video": null,
      "map_id": 34404291,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) All the above. Correct Response Explanation: Pancytopenia with a cellular marrow (reduced counts of all three blood cell lines: red blood cells, white blood cells, and platelets, despite a normal or increased number of cells in the bone marrow) can be seen in various conditions, including: MDS (Myelodysplastic Syndromes): MDS is a group of disorders caused by poorly formed or dysfunctional blood cells. It results in ineffective hematopoiesis (blood cell production) and can lead to pancytopenia. In MDS, the bone marrow is often hypercellular, meaning there are increased numbers of immature or abnormal cells, but they are ineffective at producing functional blood cells. PNH (Paroxysmal Nocturnal Hemoglobinuria): PNH is a hematological disorder characterized by hemolysis and thrombosis. Although the bone marrow is often hypercellular, it can lead to pancytopenia due to bone marrow failure. This results in insufficient production of red blood cells, white blood cells, and platelets, despite an increased number of marrow cells that are ineffective or dysfunctional. Aleukemic Leukemia: In aleukemic leukemia, there is infiltration of the bone marrow by leukemic cells, but these cells may not be present in the peripheral blood initially. The bone marrow is often hypercellular, containing an abundance of immature or malignant cells, but the peripheral blood shows pancytopenia due to the abnormal proliferation of leukemic cells that displace normal hematopoietic cells. Incorrect Response Explanations: (A) MDS: MDS itself is a correct response, as pancytopenia with a cellular marrow is a hallmark feature of myelodysplastic syndromes. The bone marrow is typically hypercellular, but ineffective hematopoiesis leads to pancytopenia. (B) PNH: PNH can also present with pancytopenia and a hypercellular bone marrow. The primary issue in PNH is the dysfunctional red blood cells, which lead to hemolysis, but bone marrow failure can result in pancytopenia, especially in advanced stages of the disease. (C) Aleukemia leukemia: Aleukemic leukemia is another condition that fits with the given finding. Aleukemia is a form of leukemia in which the leukemia cells proliferate within the bone marrow but are not yet present in the peripheral blood. The bone marrow may be hypercellular, but the peripheral blood can show pancytopenia.",
      "correct_choice_id": 256398,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/1606091705130558/1606091705130558.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/1606091705130558/1606091705130558.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 98039,
      "choices": [
        {
          "id": 256399,
          "text": "Shwachman-Diamond syndrome"
        },
        {
          "id": 256400,
          "text": "Dyskeratosis congenita"
        },
        {
          "id": 256401,
          "text": "Fanconi anemia"
        },
        {
          "id": 256402,
          "text": "Felty’s syndrome"
        }
      ],
      "text": "Not an inherited cause of aplastic anaemia ?",
      "unique_key": "Q9756208",
      "question_audio": null,
      "question_video": null,
      "map_id": 34428099,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Felty’s syndrome. Correct Response Explanation: Felty’s syndrome is not an inherited cause of aplastic anemia. It is a rare complication of rheumatoid arthritis (RA) characterized by splenomegaly, neutropenia, and pancytopenia. Although pancytopenia may occur in Felty's syndrome, it is not an inherited genetic condition but rather a secondary disorder related to chronic inflammation in RA. Therefore, it does not fit as an inherited cause of aplastic anemia. Incorrect Response Explanations: (A) Shwachman-Diamond syndrome: Shwachman-Diamond syndrome (SDS) is an inherited condition caused by mutations in the SBDS gene. It typically presents with pancytopenia and exocrine pancreatic insufficiency. Aplastic anemia can occur in these patients as part of the hematological abnormalities of the syndrome. SDS is an inherited cause of aplastic anemia. (B) Dyskeratosis congenita: Dyskeratosis congenita is an inherited disorder caused by mutations in genes involved in maintaining telomere function. It often leads to bone marrow failure, including aplastic anemia, as well as other systemic features like skin pigmentation abnormalities and nail dystrophy. It is a well-known inherited cause of aplastic anemia. (C) Fanconi anemia: Fanconi anemia is an inherited genetic disorder that leads to bone marrow failure, including aplastic anemia, due to defective DNA repair mechanisms. It is characterized by a higher predisposition to cancers and congenital abnormalities, making it another inherited cause of aplastic anemia.",
      "correct_choice_id": 256402,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/21266961705130572/21266961705130572.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/21266961705130572/21266961705130572.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 98040,
      "choices": [
        {
          "id": 256403,
          "text": "EBV"
        },
        {
          "id": 256404,
          "text": "Adenovirus"
        },
        {
          "id": 256405,
          "text": "HIV"
        },
        {
          "id": 256406,
          "text": "Parvovirus B 19"
        }
      ],
      "text": "Which of the following viruses is not associated with aplastic anaemia ?",
      "unique_key": "Q7810286",
      "question_audio": null,
      "question_video": null,
      "map_id": 34798528,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Adenovirus. Correct Response Explanation: Adenovirus is not typically associated with aplastic anemia. Adenoviruses can cause a range of infections, including respiratory, gastrointestinal, and conjunctival infections, but they are not commonly linked to the development of aplastic anemia. Unlike other viruses that directly affect bone marrow function, adenovirus is not considered a significant cause of bone marrow failure or aplastic anemia. Incorrect Response Explanations: (A) EBV (Epstein-Barr Virus): Epstein-Barr virus (EBV), a member of the herpesvirus family, has been associated with aplastic anemia, particularly in individuals with weakened immune systems or those undergoing hematopoietic stem cell transplantation. EBV can affect the bone marrow and cause pancytopenia, making it a known viral cause of aplastic anemia. (C) HIV (Human Immunodeficiency Virus): HIV is a known cause of immune-mediated bone marrow failure. HIV infection can lead to pancytopenia and aplastic anemia through various mechanisms, including direct infection of bone marrow cells, opportunistic infections, and immune-mediated destruction of blood cells. Therefore, HIV is associated with aplastic anemia, particularly in advanced stages of the disease or when the immune system is compromised. (D) Parvovirus B19: Parvovirus B19 is a well-known viral cause of aplastic anemia. It specifically targets erythroid precursor cells in the bone marrow, leading to erythroblastopenia (a reduction in red blood cell precursors). This virus can cause acute aplastic anemia, especially in individuals with underlying hematologic conditions such as sickle cell disease or those with compromised immune systems.",
      "correct_choice_id": 256404,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/19480761705130586/19480761705130586.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/19480761705130586/19480761705130586.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 98041,
      "choices": [
        {
          "id": 256407,
          "text": "Bleeding"
        },
        {
          "id": 256408,
          "text": "Splenomegaly"
        },
        {
          "id": 256409,
          "text": "Lymphadenopathy"
        },
        {
          "id": 256410,
          "text": "Both b and c"
        }
      ],
      "text": "Not a feature of aplastic anaemia ?",
      "unique_key": "Q4447606",
      "question_audio": null,
      "question_video": null,
      "map_id": 34409096,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Both b and c (Splenomegaly and Lymphadenopathy). Correct Response Explanation: Splenomegaly and Lymphadenopathy are not characteristic features of aplastic anemia. Aplastic anemia is primarily a disorder of the bone marrow where there is failure to produce blood cells, leading to pancytopenia (low red blood cells, white blood cells, and platelets). Splenomegaly (enlarged spleen) and lymphadenopathy (swollen lymph nodes) are typically seen in conditions involving increased cell turnover, such as hematologic malignancies (leukemia, lymphoma) or infections, but are not typical in aplastic anemia. Therefore, the presence of these features should raise suspicion for a different diagnosis. Incorrect Response Explanations: (A) Bleeding: Bleeding is a common feature of aplastic anemia. Aplastic anemia leads to a reduced number of platelets, causing a tendency to bleed, often manifesting as petechiae, bruising, or nosebleeds. Since the bone marrow is not producing enough blood cells, the low platelet count predisposes to bleeding. (B) Splenomegaly: As mentioned above, splenomegaly is not typically associated with aplastic anemia. Aplastic anemia usually presents with a non-enlarged spleen since it is a disorder related to bone marrow failure rather than an underlying process causing excessive blood cell production, which would lead to splenomegaly. (C) Lymphadenopathy: Lymphadenopathy is similarly not a typical feature of aplastic anemia. While it can be seen in conditions such as lymphoma, infection, or other hematologic disorders, aplastic anemia usually does not present with enlarged lymph nodes. The disease primarily affects the bone marrow and leads to pancytopenia without lymph node enlargement.",
      "correct_choice_id": 256410,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/46955901705130599/46955901705130599.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/46955901705130599/46955901705130599.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 98042,
      "choices": [
        {
          "id": 256411,
          "text": "Haematopoietic stem cell transplantation"
        },
        {
          "id": 256412,
          "text": "Antithymocyte globulin"
        },
        {
          "id": 256413,
          "text": "Eltrombopag"
        },
        {
          "id": 256414,
          "text": "All the above"
        }
      ],
      "text": "Which of the following can be used in the treatment of aplastic anaemia ?",
      "unique_key": "Q7876443",
      "question_audio": null,
      "question_video": null,
      "map_id": 34994040,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) All the above. Correct Response Explanation: All the listed treatments can be used in the management of aplastic anemia, which is a condition where the bone marrow fails to produce adequate blood cells, leading to pancytopenia. The treatment approach depends on the severity of the disease and the patient's age and general health, but all the options listed are viable: Haematopoietic stem cell transplantation (HSCT): HSCT is the treatment of choice for severe aplastic anemia, especially in younger patients with a suitable donor. It involves transplanting stem cells to restore normal bone marrow function. Antithymocyte globulin (ATG): ATG is used to modulate the immune system and treat severe aplastic anemia, particularly in patients who are not candidates for stem cell transplantation or do not have a suitable donor. It works by targeting and removing immune cells that are thought to attack the bone marrow. Eltrombopag: Eltrombopag is a thrombopoietin receptor agonist used to stimulate platelet production and can help increase blood cell production in patients with aplastic anemia. It is particularly helpful for those with non-severe aplastic anemia and those who do not respond well to conventional treatments like ATG. Thus, all of the above treatments are used in different scenarios depending on the patient's condition and response to therapy. Incorrect Response Explanations: None of the options listed are incorrect, as they are all valid treatment options for aplastic anemia, and the correct answer remains (D) All the above.",
      "correct_choice_id": 256414,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/60594051705130614/60594051705130614.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/60594051705130614/60594051705130614.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 98043,
      "choices": [
        {
          "id": 256415,
          "text": "Malignancies"
        },
        {
          "id": 256416,
          "text": "Procainamide"
        },
        {
          "id": 256417,
          "text": "SLE"
        },
        {
          "id": 256418,
          "text": "All the above"
        }
      ],
      "text": "Which of the following is associated with pure red cell aplasia (PRCA) ?",
      "unique_key": "Q4573802",
      "question_audio": null,
      "question_video": null,
      "map_id": 34692900,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) All the above. Pure red cell aplasia (PRCA) is a condition characterized by a selective reduction in red blood cell production, while other blood cell lines (white blood cells and platelets) remain unaffected. Various factors can be associated with the development of PRCA, including malignancies, medications, and autoimmune diseases. In this case, all the listed options are known to be associated with PRCA. Malignancies: Certain cancers, particularly thymoma (a tumor of the thymus), can cause PRCA due to an immune-mediated suppression of erythropoiesis. Additionally, other malignancies can cause PRCA through immune mechanisms or paraneoplastic syndromes. Procainamide: This antiarrhythmic drug is known to cause drug-induced PRCA. It can trigger an autoimmune response that leads to the destruction of red blood cell precursors in the bone marrow, resulting in PRCA. Patients taking procainamide can develop this condition as a rare side effect. SLE (Systemic Lupus Erythematosus): SLE is an autoimmune disorder in which the body's immune system attacks its own tissues. PRCA can occur as part of the disease process, often due to the production of autoantibodies that target erythropoiesis, leading to a decrease in red blood cell production. Incorrect options: Option A: Malignancies: As already discussed, malignancies, especially thymomas, are indeed associated with PRCA, so this option is correct. Option B: Procainamide: This is also correct. Procainamide is a known cause of drug-induced PRCA. Option C: SLE: SLE can lead to PRCA through immune-mediated mechanisms, and thus, this option is also correct.",
      "correct_choice_id": 256418,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/26233991705130630/26233991705130630.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/26233991705130630/26233991705130630.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 98044,
      "choices": [
        {
          "id": 256419,
          "text": "Busulfan"
        },
        {
          "id": 256420,
          "text": "Nitrosurea"
        },
        {
          "id": 256421,
          "text": "Procarbazine"
        },
        {
          "id": 256422,
          "text": "All the above"
        }
      ],
      "text": "Therapy related MDS can occur secondary to ?",
      "unique_key": "Q9313843",
      "question_audio": null,
      "question_video": null,
      "map_id": 34504907,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) All the above. Therapy-related myelodysplastic syndrome (MDS) is a condition that can occur as a secondary result of cancer treatment, particularly chemotherapy and radiation therapy. Several chemotherapy agents, including busulfan, nitrosurea, and procarbazine, have been associated with an increased risk of developing therapy-related MDS. These agents can cause DNA damage in hematopoietic stem cells, leading to the development of MDS years after the treatment. Busulfan: Busulfan is a chemotherapy agent that is well-known for its association with therapy-related MDS. It is an alkylating agent, and prolonged use can cause DNA damage to hematopoietic stem cells, leading to the development of secondary MDS. Nitrosurea: Nitrosureas, a class of chemotherapy drugs, are also associated with the development of therapy-related MDS. These drugs cause DNA cross-linking and damage to bone marrow cells, which can result in the development of MDS over time. Procarbazine: Procarbazine is another chemotherapy agent that is linked to an increased risk of secondary MDS. Like the other agents, it can cause DNA damage in hematopoietic stem cells, contributing to the development of MDS, typically after a latency period. Incorrect options: Option A: Busulfan: Busulfan is correctly associated with therapy-related MDS, so this option is correct. Option B: Nitrosurea: Nitrosureas are correctly associated with therapy-related MDS, so this option is also correct. Option C: Procarbazine: Procarbazine is similarly linked to the development of therapy-related MDS, so this option is correct as well.",
      "correct_choice_id": 256422,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/70619131705130645/70619131705130645.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/70619131705130645/70619131705130645.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 98045,
      "choices": [
        {
          "id": 256423,
          "text": "Azacitidine"
        },
        {
          "id": 256424,
          "text": "Decitabine"
        },
        {
          "id": 256425,
          "text": "Lenalidomide"
        },
        {
          "id": 256426,
          "text": "Cyclophosphamide"
        }
      ],
      "text": "Which drug is effective in treating MDS associated with 5q deletion ?",
      "unique_key": "Q4268208",
      "question_audio": null,
      "question_video": null,
      "map_id": 34663870,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Lenalidomide. Myelodysplastic syndromes (MDS) associated with 5q deletion, also known as del(5q) MDS, is a specific subtype of MDS characterized by the loss of part of the long arm of chromosome 5. Lenalidomide, an immunomodulatory drug, has been shown to be particularly effective in treating this condition. It works by modifying the immune system, enhancing the function of hematopoietic stem cells, and reducing the need for transfusions. Lenalidomide is a first-line treatment for MDS with 5q deletion, and it can significantly improve blood counts and quality of life for affected patients. Incorrect options: Option A: Azacitidine: Azacitidine is a hypomethylating agent commonly used in the treatment of MDS, but it is not specifically effective for MDS with 5q deletion. While it can help in general MDS treatment by improving blood counts, lenalidomide is the drug of choice for del(5q) MDS. Option B: Decitabine: Similar to azacitidine, decitabine is another hypomethylating agent used in MDS treatment. However, it is not specifically targeted to MDS associated with 5q deletion, so it is not as effective as lenalidomide for this particular condition. Option D: Cyclophosphamide: Cyclophosphamide is an alkylating chemotherapy agent used in various cancers, but it is not the first-line treatment for MDS with 5q deletion. It is generally not effective for this specific type of MDS compared to lenalidomide.",
      "correct_choice_id": 256425,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/13851431705130661/13851431705130661.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/13851431705130661/13851431705130661.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 98046,
      "choices": [
        {
          "id": 256427,
          "text": "Hepatopulmonary syndrome"
        },
        {
          "id": 256428,
          "text": "Renal artery stenosis"
        },
        {
          "id": 256429,
          "text": "2,3 BPG mutation"
        },
        {
          "id": 256430,
          "text": "All the above"
        }
      ],
      "text": "Erythrocytosis is associated with ?",
      "unique_key": "Q4162813",
      "question_audio": null,
      "question_video": null,
      "map_id": 34729899,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) All the above. Erythrocytosis refers to an increase in the number of red blood cells in the bloodstream, which can occur due to various underlying conditions. All the options listed — hepatopulmonary syndrome, renal artery stenosis, and 2,3-BPG mutation — are associated with erythrocytosis. Each condition leads to compensatory erythropoiesis (the production of red blood cells) in response to hypoxia or altered oxygen delivery, causing increased red blood cell mass. Hepatopulmonary syndrome: This syndrome is a condition where liver disease leads to the development of pulmonary vascular abnormalities that impair oxygenation, resulting in hypoxemia. In response to this low oxygen level, the body may increase erythropoiesis, leading to erythrocytosis as a compensatory mechanism. Renal artery stenosis: Renal artery stenosis, which is the narrowing of the arteries that supply blood to the kidneys, can lead to reduced kidney perfusion and oxygen delivery. The kidneys respond by producing more erythropoietin (EPO), a hormone that stimulates red blood cell production, which can result in erythrocytosis. 2,3-BPG mutation: A mutation in the gene responsible for 2,3-bisphosphoglycerate (2,3-BPG), a molecule that regulates hemoglobin's oxygen affinity, can cause hemoglobin to release oxygen less efficiently to tissues. This leads to tissue hypoxia, which stimulates increased erythropoiesis, thereby resulting in erythrocytosis. Incorrect options: Option A: Hepatopulmonary syndrome: As explained above, this syndrome is associated with hypoxia and compensatory erythropoiesis, making it a correct option. Option B: Renal artery stenosis: Renal artery stenosis also triggers erythropoiesis through hypoxia-induced EPO release, making this option correct as well. Option C: 2,3-BPG mutation: This mutation causes oxygen release issues at the tissue level, which leads to hypoxia and an increase in erythropoiesis, making this option correct.",
      "correct_choice_id": 256430,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/53493071705130673/53493071705130673.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/53493071705130673/53493071705130673.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 98047,
      "choices": [
        {
          "id": 256431,
          "text": "7p"
        },
        {
          "id": 256432,
          "text": "9p"
        },
        {
          "id": 256433,
          "text": "7q"
        },
        {
          "id": 256434,
          "text": "9q"
        }
      ],
      "text": "JAK2 gene is located on ?",
      "unique_key": "Q4885591",
      "question_audio": null,
      "question_video": null,
      "map_id": 34522923,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) 9p. The JAK2 gene is located on chromosome 9, specifically at the short arm (p) of chromosome 9, at the position 9p24.1. Mutations in this gene, particularly the V617F mutation, are commonly associated with myeloproliferative disorders such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis. The JAK2 gene encodes a tyrosine kinase involved in the signaling pathways that regulate blood cell production, and mutations in this gene lead to uncontrolled cell proliferation. Incorrect options: Option A: 7p: The JAK2 gene is not located on chromosome 7p. Chromosome 7 does contain other important genes, but JAK2 is not one of them, making this option incorrect. Option C: 7q: The JAK2 gene is not located on chromosome 7q. While chromosome 7 does carry several other genes, the JAK2 gene is specifically located on chromosome 9, making this option incorrect. Option D: 9q: While the JAK2 gene is located on chromosome 9, it is found on the short arm (p), not the long arm (q). Therefore, this option is incorrect.",
      "correct_choice_id": 256432,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/37181951705130688/37181951705130688.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/37181951705130688/37181951705130688.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 98048,
      "choices": [
        {
          "id": 256435,
          "text": "Increased blood viscosity"
        },
        {
          "id": 256436,
          "text": "Peptic ulcer"
        },
        {
          "id": 256437,
          "text": "Pruritus"
        },
        {
          "id": 256438,
          "text": "All the above"
        }
      ],
      "text": "Which of the following can be a feature of polycythemia vera (PV) ?",
      "unique_key": "Q1254028",
      "question_audio": null,
      "question_video": null,
      "map_id": 34255618,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Polycythemia vera (PV) is a type of blood cancer characterized by the overproduction of red blood cells. Common features include: A. Increased blood viscosity – Due to elevated red cell mass, leading to sluggish blood flow and risk of thrombosis. B. Peptic ulcer – Can occur due to increased histamine levels from basophils and mast cells. C. Pruritus – Especially after a hot bath (aquagenic pruritus), due to histamine release.",
      "correct_choice_id": 256438,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/2418751705130704/2418751705130704.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/2418751705130704/2418751705130704.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 98049,
      "choices": [
        {
          "id": 256439,
          "text": "Imatinib"
        },
        {
          "id": 256440,
          "text": "Dasatinib"
        },
        {
          "id": 256441,
          "text": "Nilotinib"
        },
        {
          "id": 256442,
          "text": "Ruxolitinib"
        }
      ],
      "text": "Which JAK2 inhibitor can be used in the treatment of polycythemia vera ?",
      "unique_key": "Q9244957",
      "question_audio": null,
      "question_video": null,
      "map_id": 34712013,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Ruxolitinib. Ruxolitinib is a Janus kinase (JAK) inhibitor that is specifically used in the treatment of polycythemia vera (PV), especially in patients who are resistant or intolerant to first-line therapies such as phlebotomy or hydroxyurea. PV is associated with a JAK2 V617F mutation, and ruxolitinib works by inhibiting the JAK-STAT pathway, which is aberrantly activated in PV. By targeting this pathway, ruxolitinib reduces the overproduction of blood cells and helps manage symptoms of PV, including splenomegaly and thrombosis risk. Incorrect options: Option A: Imatinib: Imatinib is a tyrosine kinase inhibitor used primarily in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GISTs). It targets the BCR-ABL fusion protein and is not effective in treating polycythemia vera, which is driven by JAK2 mutations rather than BCR-ABL. Option B: Dasatinib: Dasatinib is another tyrosine kinase inhibitor used for CML and Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). Like imatinib, it targets BCR-ABL and does not target the JAK2 pathway, making it ineffective for PV. Option C: Nilotinib: Nilotinib, like imatinib and dasatinib, is a tyrosine kinase inhibitor that targets the BCR-ABL protein and is used for the treatment of CML. It does not address the JAK2 mutation or the underlying mechanism of PV, making it unsuitable for the treatment of polycythemia vera.",
      "correct_choice_id": 256442,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/17290211705130718/17290211705130718.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/17290211705130718/17290211705130718.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 98050,
      "choices": [
        {
          "id": 256443,
          "text": "Hyperparathyroidism"
        },
        {
          "id": 256444,
          "text": "Hairy cell leukemia"
        },
        {
          "id": 256445,
          "text": "Tuberculosis"
        },
        {
          "id": 256446,
          "text": "All the above"
        }
      ],
      "text": "Which of the following conditions can be associated with myelofibrosis ?",
      "unique_key": "Q4512254",
      "question_audio": null,
      "question_video": null,
      "map_id": 34846453,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) All the above. Myelofibrosis is a type of bone marrow disorder characterized by the replacement of normal marrow with fibrous tissue, leading to severe anemia, splenomegaly, and sometimes thrombocytosis. It can occur as a primary condition (primary myelofibrosis) or secondary to other diseases, and it has been associated with several other conditions, including hyperparathyroidism, hairy cell leukemia, and tuberculosis. Hyperparathyroidism: Hyperparathyroidism, especially when it is associated with parathyroid adenomas or chronic kidney disease, can be linked to secondary myelofibrosis. Elevated parathyroid hormone (PTH) levels can stimulate osteoclast activity, leading to bone marrow fibrosis and potentially contributing to the development of myelofibrosis. Hairy cell leukemia: Hairy cell leukemia (HCL) is a rare, chronic B-cell leukemia that is known to be associated with secondary myelofibrosis. In HCL, the infiltration of the bone marrow by leukemic cells can lead to fibrosis and the characteristic features of myelofibrosis. Tuberculosis: Tuberculosis (TB), particularly in its chronic form, can sometimes lead to secondary myelofibrosis. TB causes chronic inflammation and granulomatous tissue formation, which can spread to the bone marrow, leading to fibrosis. It is considered one of the infectious causes that may contribute to the development of myelofibrosis. Incorrect options: Option A: Hyperparathyroidism: This is a correct option because hyperparathyroidism can contribute to secondary myelofibrosis through the effects of elevated parathyroid hormone. Option B: Hairy cell leukemia: Hairy cell leukemia is correctly associated with myelofibrosis, as discussed above. Option C: Tuberculosis: Tuberculosis can lead to myelofibrosis as a secondary complication due to the chronic inflammatory process involved.",
      "correct_choice_id": 256446,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/26501481705130731/26501481705130731.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/26501481705130731/26501481705130731.m3u8",
      "question_images": [],
      "explanation_images": []
    }
  ]
}